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Abstract
Oral ulceration has many aetiological factors. The anti-
anginal drug Nicorandil is becoming increasingly recognised as 
a causative factor for oral ulceration. The aim of this case report 
is to increase awareness among clinicians (medical and dental) 
that nicorandil can induce extensive oral ulceration and thus 
should be included in the differential diagnosis when presented 
with patients complaining of long-standing oral ulceration.
 
Case report
Traditionally, standard treatment of angina pectoris has been 
based on life style changes as well as the use of pharmaceutical 
agents such as nitrates, beta-blockers and calcium-channel 
blockers. In cases intolerant of standard treatment or where 
standard treatment has failed, nicorandil may be used.
Nicorandil (Ikorel®, Rhône-Poulenc Rorer Ltd) is a 
potassium-channel activator with a nitrate component. It is 
both an arterial- and veno-dilator and is licensed for the long-
term treatment of angina. It is usually well tolerated with main 
reported side-effects of headache and cutaneous vasodilation. 
Oral ulceration has been reported to be a rare side effect. 
However several reports in the literature show that 
nicorandil–induced oral ulceration can be quite extensive, 
severe and debilitating.1-4 Furthermore, the important 
distinction between nicorandil-induced oral ulceration and 
other causes of oral ulceration, including oral carcinoma, has to 
be made due to the different subsequent treatment modalities. 
Although nicorandil was first used in Europe around 1994, its 
association with oral ulceration only came to light in 19975, thus 
its incidence might have been under-reported. This case report 
describes the presentation and management of such a case. 
An 82 year-old lady was referred by her general medical 
practitioner complaining of oral ulceration. Her main complaint 
was that of a large, painful ulcer of 9 weeks duration. Her 
past medical history showed that she suffered from cardiac 
problems namely atrial fibrillation, angina, hypertension 
as well as hypothyroidism, oesophagitis and diverticular 
disease. A malignant melanoma on her left toe was removed 
surgically 8 years previously. Her medication consisted of 
losartan, amiodarone, omeprazole, bisoprolol, spironolactone, 
temazepam, simvastatin, thyroxine, warfarin, GTN spray and 
nicorandil 20 mg twice daily.  
On clinical examination the ulcer was a soft, superficial, 
non-indurated lesion on the right dorso-lateral surface of her 
tongue, measuring 2.5 x 1.5 cm (Figure 1a). The ulcer was flat 
and had an erythematous, serpiginous outline. It did not have 
rolled borders, did not bleed and the tongue was mobile. Local 
factors e.g. trauma, haematinic deficiencies and systemic 
diseases were excluded as causes of the ulcer. Nicorandil 
seemed to be the likely cause for the ulcer. Some symptomatic 
relief was obtained with betamethasone mouthwash (0.5mg, 4 
times daily).  Following consultation with her cardiologist, the 
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Figure 1a: Ulcer on presentation Figure 1b: Six weeks after reduction of nicorandil therapy
nicorandil was reduced to 10 mg twice daily. Thereafter, the pain 
decreased and the ulcer healed in short order (six weeks) without 
any residual scarring (Figure 1b). On review three months later, 
the patient was still symptom-free through there was still some 
depapillation at the previous ulcer site. 
Discussion
Systemic medication is known to have potential adverse 
side effects on the oral mucosa. Perhaps the most common 
manifestation is gingival hyperplasia due to phenytoin, 
nifedipine and cyclosporin. Xerostomia is a common complaint 
of patients on anti-depressants and antihypertensives, while 
lichenoid reactions of the oral mucosa have been associated 
with many drugs. Oral ulceration is known to occur with 
aspirin (chemical burn, if left to dissolve whilst in contact with 
the oral mucosa), captopril, gold salts, penicillamine, NSAIDS 
and cytokine inhibitors.6  Other drugs e.g. griseofulvin and 
isoniazide have potential side effects of which oral ulceration 
may be a manifestation.  
The most common side effect of nicorandil is headache 
which manifests in the first few days of treatment but decreases 
with prolonged use. Other side effects include cutaneous 
vasodilatation with flushing, nausea, vomiting, dizziness and 
weakness; rare side effects include, myalgia, rash, reduction 
in blood pressure and / or increased heart rate, angioedema, 
hepatic dysfunction, anal ulceration and oral ulceration.6
Nicorandil-induced oral ulceration seems to have a 
predilection for the tongue though other sites e.g. buccal mucosa 
/ labial mucosa1,4, gingiva1,7 may also be affected.  The exact 
mechanism of ulcer formation is unknown. Although described 
a rare occurrence, its incidence has been reported to be around 
5%7. Some case reports have shown that nicorandil seems to be 
associated with ulceration of other parts of the gastrointestinal 
tract: anus8, gastrointestinal tract9 and para-stomally.10  King et 
al.11 also report perforation of the terminal ileum as a possible 
complication of nicorandil therapy.
This case report presents a fairly typical picture of nicorandil-
induced oral ulceration. Resolution of symptoms following 
reduction in dose confirmed the diagnosis. The appearance of 
ulcers seems to be dose-dependent with most patients (as in this 
case) being on at least 40 mg nicorandil daily.2-4 
Although clinically they may appear like aphthous ulcers12, 
and have been reported as such13,14, nicorandil-induced oral 
ulcers have certain distinguishing features. Clinically they are 
larger than minor aphthous ulcers and have an irregular outline. 
Furthermore they appear on keratinized mucosa (tongue) whilst 
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major aphthae never appear at this site. The lateral border of 
the tongue is the primary site for oral squamous cell carcinoma 
(OSCC); certain clinical features distinguish between the two 
conditions: nicorandil-induced oral ulcers are painful from 
the outset whilst OSCC may become painful only in the late 
stages of the disease. Furthermore, an OSCC would normally 
present as an indurated, exophytic lesion or as a red, white or 
speckled patch. 
It is important to point out that this patient had presented 
two years earlier with a similar large, sloughing, irregular ulcer 
on her left cheek. At the time she was on 30 mg nicorandil twice 
daily. Treatment followed a similar pattern as above. However 
at that time she was lost to follow up. 
It is recognised that nicorandil causes mouth ulceration; 
however the mechanism by which it does so remains unknown. 
Ulceration is more likely to occur with higher doses of the drug 
(> 40 mg daily). What is noteworthy is that cessation of the drug 
is not normally required, with a reduction in dose providing 
relief from ulceration in most patients.
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